Oculis Holding AG
OCSNASDAQHealthcare● Active
$10.71
$-0.50(-4.46%)
Market Cap$612285345
P/E Ratio—
52W High$34.475
52W Low$10.52
Oculis Holding AG (OCS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OCS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.63
Est. -$0.49 · -28.6%
Revenue
$0.00B
Est. $0.00B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
OCS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.48 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.49 | -$0.63 | -28.6% | $0.00B | $0.00B | -0.2% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$0.48 | -$0.51 | -6.7% | $0.00B | $0.00B | +262.8% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.50 | -$0.40 | +20.0% | $0.00B | $0.00B | +123.2% |
| ▼ Q3 FY2025 | Aug 21, 2025 | -$0.53 | -$0.59 | -11.3% | $0.00B | $0.00B | +129.2% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.51 | -$0.77 | -51.0% | $0.00B | $0.00B | +48.0% |
| ▼ Q1 FY2025 | Mar 11, 2025 | -$0.48 | -$0.76 | -58.3% | $0.00B | $0.00B | -97.7% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.52 | -$0.55 | -5.8% | $0.00B | $0.00B | -9.2% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.63
EPS Est.
-$0.49
EPS Surpr.
-28.6%
Revenue
$0.00B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$0.51
EPS Est.
-$0.48
EPS Surpr.
-6.7%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.50
EPS Surpr.
+20.0%
Revenue
$0.00B
Q3 FY2025
Aug 21, 2025Miss
EPS Actual
-$0.59
EPS Est.
-$0.53
EPS Surpr.
-11.3%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.77
EPS Est.
-$0.51
EPS Surpr.
-51.0%
Revenue
$0.00B
Q1 FY2025
Mar 11, 2025Miss
EPS Actual
-$0.76
EPS Est.
-$0.48
EPS Surpr.
-58.3%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.55
EPS Est.
-$0.52
EPS Surpr.
-5.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.65 | $-0.47 | $-0.40 | 2 |
| Q3 FY2027 | $-0.62 | $-0.44 | $-0.38 | 2 |
| Q2 FY2027 | $-0.57 | $-0.41 | $-0.35 | 2 |
| Q1 FY2027 | $-0.56 | $-0.40 | $-0.35 | 2 |
| Q4 FY2026 | $-0.62 | $-0.44 | $-0.38 | 4 |
| Q3 FY2026 | $-0.46 | $-0.42 | $-0.39 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -28.6% | $32.64 | $32.65 | +0.03% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -6.7% | $28.61 | $27.57 | -3.64% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +20.0% | $19.23 | $19.42 | +0.99% |
| ▼ Q3 FY2025 | Aug 21, 2025 | -11.3% | $17.55 | $17.80 | +1.42% |
| ▼ Q2 FY2025 | May 8, 2025 | -51.0% | $18.42 | $18.70 | +1.52% |
| ▼ Q1 FY2025 | Mar 11, 2025 | -58.3% | $18.30 | $18.40 | +0.55% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -5.8% | $16.89 | $16.80 | -0.53% |
| ▼ Q3 FY2024 | Aug 27, 2024 | -30.2% | $11.85 | $11.91 | +0.51% |
Q2 FY2026+0.03%
Report Date
May 11, 2026
EPS Beat/Miss
-28.6%
Price Before
$32.64
Price After
$32.65
Q1 FY2026-3.64%
Report Date
Mar 3, 2026
EPS Beat/Miss
-6.7%
Price Before
$28.61
Price After
$27.57
Q4 FY2025+0.99%
Report Date
Nov 10, 2025
EPS Beat/Miss
+20.0%
Price Before
$19.23
Price After
$19.42
Q3 FY2025+1.42%
Report Date
Aug 21, 2025
EPS Beat/Miss
-11.3%
Price Before
$17.55
Price After
$17.80
Q2 FY2025+1.52%
Report Date
May 8, 2025
EPS Beat/Miss
-51.0%
Price Before
$18.42
Price After
$18.70
Q1 FY2025+0.55%
Report Date
Mar 11, 2025
EPS Beat/Miss
-58.3%
Price Before
$18.30
Price After
$18.40
Q4 FY2024-0.53%
Report Date
Nov 7, 2024
EPS Beat/Miss
-5.8%
Price Before
$16.89
Price After
$16.80
Q3 FY2024+0.51%
Report Date
Aug 27, 2024
EPS Beat/Miss
-30.2%
Price Before
$11.85
Price After
$11.91
Avg Beat Reaction+0.99%
Avg Miss Reaction-0.02%
Beat Rate1 / 8 quarters
Largest Move-3.64% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OCS ends December
Oculis Holding AG (OCS) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.63 — missing the analyst consensus of $-0.49 by -28.6%. The next OCS earnings date is expected around September 1, 2026.
Each quarter, investors track OCS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OCS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OCS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OCS earnings · 5 questionsOculis Holding AG's next earnings report is expected around September 1, 2026. OCS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OCS historically reports after market close (AMC).
OCS earnings datewhen is OCS earningsOCS next earnings datewhen does OCS report earningsOCS earnings calendar
▸ Source: FMP · Oculis Holding AG SEC filings · US GAAP · Oculis Holding AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026